At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
ATYR1940biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
In Brief
A Phase 2 clinical trial evaluating ATYR1940 for Facioscapulohumeral Muscular Dystrophy (FSHD). Completed, enrolled 8 participants across 7 sites in 3 countries.
Detailed Summary
The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with early onset FSHD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Italy, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartMar 2016
Primary CompletionDec 2016
TodayJul 2026
First PostedNov 13, 2015
Enrollment StartMar 30, 2016
Primary CompletionDec 12, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.6 years ago
Interventions
ATYR1940biological
Concentrate for solution for infusion